Categories
Health

U.Ok. Approves Johnson & Johnson Vaccine

Britain’s drug regulator on Friday approved the use of the single-dose shots manufactured by Johnson & Johnson, the fourth coronavirus vaccine to be authorized in the country.

The authorization comes amid growing concerns about the spread in Britain of a coronavirus variant first detected in India. The number of cases of the variant, known as B.1.617.2, has doubled in a week, according to public data, and as of Thursday, nearly 7,000 cases had been detected.

“This fourth approved vaccine adds to our armory,” the British health secretary, Matt Hancock, said on Twitter. “When you’re eligible, get your jab.” Britain has also authorized the use of the vaccines manufactured by Moderna, Oxford-AstraZeneca and Pfizer-BioNTech.

More than 58 percent of Britain’s population has received at least one dose of a coronavirus vaccine, and 36 percent has been fully vaccinated. Britain opened vaccination to adults 30 and older this week, but most of the vaccination campaign’s efforts have in recent weeks focused on second injections.

Johnson & Johnson’s vaccine is 85 percent effective against severe illness from Covid-19, according to the British regulator.

The approval in Britain comes a day after Mexico gave emergency authorization to the same vaccine.

The Mexican government has previously authorized the vaccines from AstraZeneca and Pfizer, as well as Russia’s Sputnik V and China’s Sinovac and CanSino.

In other news around the world:

  • The regional government of Madrid announced on Friday that it would use AstraZeneca’s vaccine for second doses for people under 60, going against a recommendation by Spain’s central government to switch to Pfizer-BioNTech’s vaccine for the second shot. While European Union regulators have said AstraZeneca’s vaccine is safe, it has continued to create tension in Spain, one of the countries that suspended its use briefly in March after reports of blood clots.

  • The Indian government is in talks with Pfizer to obtain 50 million doses of the company’s coronavirus vaccine starting this summer, but is still considering the drug manufacturer’s demand for indemnity from costs related to severe side effects, officials have said.

  • Hong Kong on Thursday recorded no new coronavirus cases for the first time in seven months, a promising sign in the Chinese territory’s efforts to quash a wave of infections that began in November. The city has gone more than a month without recording more than 15 daily cases, increasing calls for the authorities to relax social-distancing measures.

  • Vietnam ordered religious establishments to suspend large gatherings after a cluster of infections was linked to a Protestant congregation in Ho Chi Minh City, part of a nationwide surge in cases. Of more than 6,300 total cases recorded in the Southeast Asian nation since the start of the pandemic, half have come in the past month, the state-run Vietnam News Agency reported.

Categories
Health

Summer time to be low danger for Covid, however winter might be difficult

The coronavirus threat in the US is likely to be on the low side this summer, but there is no guarantee that it will stay that way later this year, said Dr. Scott Gottlieb told CNBC on Friday.

“I don’t think we should declare the mission accomplished. I think we should declare a short-term victory,” the former commissioner of the Food and Drug Administration said on Squawk Box.

Coronavirus cases in the country have fallen as more Americans are vaccinated against Covid. According to a CNBC analysis of Johns Hopkins University data, the 7-day average of new infections a day is 23,000. That has fallen by more than 50% since the beginning of May alone.

“I think we’ve done enough to give ourselves the opportunity to enjoy the summer and take a low risk this summer,” said Gottlieb, who headed the FDA from 2017 to 2019 and is now on the board of directors at vaccine company Pfizer . However, he added, “I think this will be a risk when we get into autumn and probably earlier into winter.”

Later on at CNBC, Gottlieb stated that he believed the risk was likely to increase in December and January.

“I think there are pockets all over the country that have low vaccination rates, that have people who haven’t been infected, so you’re going to see outbreaks. I don’t think we’re going to see anything on the scale of that, what we’ve seen in the past, “said Gottlieb to” Closing Bell “. “I think the public health steps we are going to take will be reactive, not proactive,” he added.

One reason for the cautious outlook for the colder months is that “we were able to see new variants,” said Gottlieb, who previously determined that respiratory pathogens such as the coronavirus generally spread more easily in winter. “I think we need to get better monitoring and sequencing of the strains so we can spot these variants faster,” he said.

The US cannot relax its efforts to have more people vaccinated either, said Gottlieb. This is a key factor in reducing risk across the country.

Around 50% of the country’s population had received at least one dose by Thursday, according to the Centers for Disease Control and Prevention. Gottlieb suggested that around 75% of the country could be vaccinated by the fall.

“So there is still a lot to be done. Right now we are on a pretty good way to do the right things,” he said.

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, genetic testing startup Tempus, healthcare technology company Aetion, and Illumina biotech. He is also co-chair of the Healthy Sail Panel for Norwegian Cruise Line Holdings and Royal Caribbean.

Categories
Health

Poor Individuals Extra Prone to Have Respiratory Issues, Examine Finds

But that has changed drastically. By the survey period 2017-18, current and former smoking rates among the wealthiest dropped by nearly half to 34 percent — while rates among the poorest inched up to 57.9 percent

Though smoking is an acquired habit, lower-income people may be more likely to use tobacco to cope with the stresses of poverty, Dr. Gaffney said. Tobacco advertising often targets low-income communities, and there is a higher density of tobacco stores in poor neighborhoods, according to the authors of a commentary accompanying the study. Poor people may also have more limited access to smoking cessation programs and replacement therapies, they said.

“We’re increasingly thinking of tobacco dependence as a disease,” said Dr. Sarath Raju, an assistant professor of pulmonary and critical care medicine at Johns Hopkins University and one of the authors of the commentary. “Individual responsibility is important, but without appropriate treatment or access to treatment to help you quit, that’s a challenge.”

Among children, asthma rates increased in all income groups after 1980, but they rose more sharply among children from poorer households. There was little difference in asthma rates in young children aged 6 to 11 before 1980, which stood at 3 percent to 4 percent. But by 2017-18, rates among the poor increased to 14.8 percent, compared with 6.8 percent among children from the highest income families. (A similar pattern emerged among adults; statistical adjustments for smoking only slightly reduced the differences.)

Among low-income adults, rates of chronic obstructive pulmonary disease, an inflammatory lung disease, have long been higher than among wealthier individuals. But rates have increased, widening the gap, with prevalence among the poorest Americans increasing to 16.3 percent from 10.4 percent, even as the rate remained stable, at 4.4 percent, among the wealthiest.

Between 1959 and 2019, poorer and less-educated adults consistently reported more troubling respiratory symptoms, like labored breathing, than wealthier, more educated people. For some symptoms, like having a problem cough, the gap between the rich and poor widened over time.

Wheezing rates fell for the highest income and most educated groups, but they remained stable in the poor, least educated groups, the study found.

Categories
Health

Every day U.S. knowledge on Might 28

A young man receives his Covid-19 vaccination at a vaccination clinic. People receive the Moderna vaccine in Milford, Pennsylvania.

Preston Ehrler | LightRocket | Getty Images

Roughly half of all Americans have received at least one dose of a Covid vaccine, based on Centers for Disease Control and Prevention data published Thursday, as nationwide infection levels continued their downward trend.

New Covid cases are 23,033 per day, on a seven-day average, down 21% from a week prior, according to data compiled by Johns Hopkins University.

U.S. share of the population vaccinated

CDC data shows 49.9% of the U.S. population has received one shot or more, with 40% having completed a full vaccination program.

Among those aged 18 and older, 62% are at least partially vaccinated.

Data in a Kaiser Family Foundation survey published Friday suggests that adult vaccination rates could reach 70% in the next few months. President Joe Biden is aiming to hit that target by July 4.

In addition to 62% of survey respondents reporting they have received one dose or more, 4% said they want the vaccine as soon as possible. Another 4% of adults — who said they want to “wait and see” before getting a shot — reported that they have already scheduled an appointment or plan to get the vaccine in the next 3 months.

The share of respondents saying they will “definitely not” get vaccinated or only do so if required has remained steady at around 20% in the past few monthly Kaiser Foundation surveys.

U.S. vaccine shots administered

About 1.6 million vaccine shots have been reported administered each day on average over the past week, CDC data shows.

A handful of states have reported that vaccine incentive programs have increased local vaccination numbers in some demographics after recent drops.

U.S. Covid cases

The seven-day average of daily U.S. Covid cases was 23,033 as of Thursday, down more than 6,000 from a week ago, according to Johns Hopkins data.JHU

Case counts have not been this low since June 2020.

Average daily case counts have fallen by 5% or more in 43 states and the District of Columbia over the past week, a CNBC analysis of Johns Hopkins data shows.

In some countries outside of the U.S., infection levels are rising. Bahrain, for example, has seen a record-setting spike in cases since the beginning of May despite having 55% of its population vaccinated with at least one dose, according to data from Our World in Data.

U.S. Covid deaths

The latest seven-day average of daily U.S. Covid deaths is 667, JHU data shows, though the release of backlogged data from multiple states in recent days obscures the latest trend.

Wednesday’s figures included 373 deaths reported for Oklahoma, which the state announced is part of an “ongoing effort to investigate and reconcile backlog of COVID-19 related deaths.”

Maryland on Thursday added about 500 previously unreported deaths to its totals.

In some situations, state health departments will attribute a batch of previously unreported cases or deaths to a single day, even if those may have occurred previously. The data may be updated to reflect different dates in the future.

Prior to the reporting issues this week, the daily death toll had been on the decline for weeks.

Categories
Health

70 % Covid Vaccination Fee Might Be in Attain, New Ballot Suggests

A new poll suggests the US may be on track to vaccinate at least 70 percent of the adult population against Covid-19 by the summer.

In the latest survey by the Kaiser Family Foundation, 62 percent of respondents said they had received at least one dose of vaccine, up from 56 percent in April. At the same time, around a third of those classified as “waiting” stated that they had already made vaccine appointments or that they would have planned to do so shortly.

Dr. William Schaffner, National Infectious Disease Foundation medical director and vaccine expert, found the results encouraging.

“I think there are many people on the fence worried about things moving too fast and possible side effects. However, those concerns will be allayed as more friends and acquaintances celebrate the vaccination,” said Dr. Schaffner, who did not participate in the monthly survey, the Covid-19 Vaccine Monitor.

“You get a growing sense of comfort and security that ‘people like me’ will be vaccinated,” which he said was essential in building confidence in the vaccines.

The two populations that saw the largest increases in vaccination rates from April to May were Latino adults (from 47 percent to 57 percent) and adults without a college degree (from 48 percent to 55 percent).

The telephone survey of 1,526 adults was conducted in English and Spanish from May 18-25.

On May 10, the Food and Drug Administration approved Pfizer and BioNTech’s vaccine for children 12 years and older. The survey found that 40 percent of parents said either their child has already received at least one dose or will soon receive one.

However, the parents of younger children were much more cautious. Only about a quarter expressed willingness to have their children vaccinated once the shots have been approved for them.

The results suggest that efforts to protect as many young students as possible from Covid-19 at the start of the school year may face obstacles.

While public health experts welcomed the continued improvement in vaccination rates, they found that the pool of most willing adults was shrinking.

“There is almost no low hanging fruit at this point, but there is a path to a slow but steady increase in vaccination rates through improved access, information, advocacy and incentives,” said Drew Altman, president and chief executive officer of Kaiser Family Foundation.

President Biden’s goal is to achieve 70 percent adult vaccine coverage by July 4th. Dr. Schaffner said he thought the goal was possible. “We have to work harder,” he said.

The survey authors said the target was realistic because in addition to 62 percent of adults who received at least one dose, another 4 percent said they wanted the shot as soon as possible and another 4 percent – a third of the ” “wait and see” group said they had made an appointment or intend to do so within three months.

Despite the positive news, vaccination rates in adults who previously reported significant hesitation (7 percent) or outright rejection (13 percent) have remained unchanged for several months. And a third of the “wait and see” group said they would wait at least a year before taking the picture.

The survey also looked at attitudes towards vaccination incentives and the impact of government news about the shots. Financial incentives, such as the million dollar lottery in Ohio for the newly vaccinated, are being pushed back a little.

However, the survey found that such rewards can be successful motivators for people to get the shots. Fifteen percent of non-vaccinated adults in the survey said their state’s offer of $ 100 may make them reconsider, as well as free transportation and tickets to a sporting event or concert.

Earlier this month, people vaccinated at an event at Talladega Superspeedway in Alabama were able to complete two winning laps on the track. (Cars and trucks, yes; motorcycles, no.) Similar incentives are being offered across the country.

About 20 percent of unvaccinated workers said they would be more likely to get the shots if their employer gave them paid time off for the dates and time needed to recover from side effects.

The report also showed that the public had some confidence in the government’s health-related messages, although many were confused by the Centers for Disease Control and Prevention’s announcement earlier this month that vaccinated people could largely avoid face masks and social distancing. Over half said the CDC’s guidelines were generally clear and accessible, but about 40 percent found them confusing and cloudy.

Notably, 85 percent of people who were not vaccinated said that the CDC’s new guidelines no longer made them ready to be vaccinated.

But another cohort viewed government approval as a potential launch vehicle. The survey found that a third of unvaccinated adults, including 44 percent in the “wait and see” group, said they would be more likely to receive a vaccine once it received full approval from the Food and Drug Administration. Vaccine makers Moderna and Pfizer-BioNTech recently announced that they are making progress towards this goal.

Categories
Health

Elizabeth Holmes’ attorneys cite unfavourable protection in request to develop jury choice

Elizabeth Holmes, founder and former executive director of the Theranos Center, is leaving the U.S. Federal Court in San Jose, California on May 6, 2021.

Nina Riggio | Bloomberg | Getty Images

In the case of Elizabeth Holmes, it seems that any advertisement is not a good advertisement.

Attorneys for the former Theranos CEO cite widespread negative media coverage as a reason to add to the pool of jurors in their upcoming criminal trial.

A 21-page motion filed late Thursday set out examples of extremely descriptive and unflattering stories about Holmes in recent years.

“The advertising is consistently negative,” said Holmes lawyers. In addition, she is “routinely mentioned in derisive and inflammatory terms directly relevant to the cable fraud charges in this case. Media coverage describes her as” fraud “,” cheater “,” cheater “,” more ashamed. ” Theranos Founder “. Cheater and an angry psychopath.

Holmes requests an extended subpoena from the jury and has proposed a written questionnaire for the jury. Holmes attorneys wrote, “Media coverage also addresses adverse tropes and recurring issues, often related to Ms. Holmes’ behavior, voice and physical appearance.” They say the negative publicity dates back to at least 2015 and “has focused intensely on Ms. Holmes personally, not just the circumstances surrounding the dissolution of Theranos’ company”.

In the court record, Holmes’ lawyers said they conducted a comprehensive search of news articles and other media that generated 462,000 entries. These included 3,755 results from “Negative Personal News” and 2,862 results from “Negative Business News”.

Holmes attorneys proposed a 46-page jury questionnaire covering topics ranging from working in the blood test or the medical industry to experience in the venture capital world.

The questionnaire also asks whether the prospective juror has ever been a victim of fraud, had a bad experience with an investment, or was involved in a dispute over misdiagnosis.

Holmes left Stanford at the age of 19 and founded Theranos. He claimed his technology could accurately perform thousands of tests on just a drop or two of blood. The former executive has pleaded guilty to under a dozen fraud charges relating to misleading patients and investors.

The judge has scheduled a court hearing on June 15th. The jury selection is scheduled to begin in San Jose on August 31st.

Categories
Health

Why Apple and Google’s Virus Alert Apps Had Restricted Success

Sarah Cavey, a Denver real estate agent, was delighted last fall when Colorado rolled out an app to warn people of potential coronavirus exposures.

Based on software from Apple and Google, the government smartphone app uses Bluetooth signals to recognize users who are in close contact. If a user later tests positive, that person can anonymously notify other app users that the person may have crossed over with on restaurants, trains, or elsewhere.

Ms. Cavey immediately downloaded the app. After testing positive for the virus in February, she couldn’t get the special verification code she needed from the state to warn others, she said, even after calling the Colorado Health Department three times.

“You promote this app to make people feel comfortable,” said Ms. Cavey, adding that she has since deleted the CO Exposure Notifications app in frustration. “But it doesn’t really matter.”

The Colorado Health Department said they have improved their process and are now automatically issuing verification codes to anyone in the state who test positive.

When Apple and Google announced last year that they were working together to create a smartphone-based system to contain the virus, their collaboration seemed like a game changer. Human contact tracers have struggled to keep up with the rise in virus levels, and the trillion-dollar competing companies, whose systems power 99 percent of the world’s smartphones, had the potential to quickly and automatically alert far more people.

Soon after, Austria, Switzerland, and other nations introduced virus apps based on Apple’s Google software, as did around two dozen American states, including Alabama and Virginia. According to an analysis by Sensor Tower, an app research company, the apps have been downloaded more than 90 million times to date.

However, some researchers say that companies’ product and policy decisions limited the usefulness of the system, raising questions about big tech’s ability to set global standards for public health tools.

Computer scientists have reported accuracy issues with Bluetooth technology, which is used to detect proximity between smartphones. Some users have complained about failed notifications. So far, there has hardly been any rigorous research into whether the apps’ potential to precisely alert people to virus loads outweighs potential disadvantages – for example, incorrectly warning not exposed people, over-testing or not recognizing users who are exposed to the virus.

“It’s still an open question whether these apps help, or just distract, or even cause problems with real-world contact tracing,” Stephen Farrell and Doug Leith, computer science researchers at Trinity College Dublin, wrote an April report on Ireland’s virus alert- App.

In the United States, some public health officials and researchers said the apps had shown modest but important benefits. In Colorado, more than 28,000 people have used the technology to inform contacts of potential virus exposures. In California, where a virus tracking app called CA Notify was launched in December, around 65,000 people have used the system to alert other app users.

“Exposure notification technology has shown success,” said Dr. Christopher Longhurst, UC San Diego Health’s chief information officer, who manages the California app. “Whether it’s hundreds of lives saved or dozens or a handful, when we save lives it’s a big deal.”

In a joint statement, Apple and Google said, “We are proud to work with health officials to provide a resource that has enabled millions of people around the world and that has helped protect public health.”

Let us help you protect your digital life

The Apple and Google system, based in part on ideas developed by the Singapore government and scientists, includes privacy measures that provide health officials with an alternative to more invasive apps. Unlike virus tracking apps, which continuously track users’ whereabouts, Apple and Google software use Bluetooth signals that can estimate the distance between smartphones without knowing where users are. It also uses rotating ID codes – not real names – to log app users who have been in close contact for 15 minutes or more.

Some health officials predicted last year that the technology could inform users of virus exposure faster than human contact tracers. Others hoped the apps could warn commuters sitting next to an infected stranger on a bus, train, or plane – people at risk who contact tracers typically cannot identify themselves.

“Everyone who uses the app helps to keep the virus under control,” said Chancellor Angela Merkel in a video to advertise the country’s warning system called Corona-Warn-App last year.

However, the apps never received the extensive efficacy tests that were normally done before governments introduced public health interventions such as vaccines. And the software’s privacy features, which prevent government agencies from identifying app users, have made it difficult for researchers to determine if the notifications were hindering the transmission of viruses, said Michael T. Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota.

“The apps played virtually no role in investigating any outbreaks that occurred here,” said Dr. Osterholm.

Some restrictions already occurred before the apps were released. For one, some researchers find that exposure notification software inherently excludes certain vulnerable populations, e.g. B. older people who cannot afford smartphones. Second, the apps could trigger false positives as the system is not set up to take damage control factors into account, e.g. B. whether users are vaccinated, wearing masks or sitting outside.

Proximity detection in virus alert apps can also be inconsistent. Last year, a study of Google’s system for Android phones carried out on a Dublin tram reported that the metal walls, floors and ceilings distorted Bluetooth signal strength enough that the likelihood of accurate proximity detection would be “similar” Trigger notifications by randomly selecting passengers.

Such glitches angered early adopters like Kimbley Craig, the Mayor of Salinas, California. Last December, when virus rates rose there, she downloaded the state exposure notification app on her Android phone and tested positive for Covid-19 shortly afterwards. After she entered the verification code, the system was unable to send a notification to her partner, with whom she lived and who had also downloaded the app.

“Unless it takes one person in the same household, I don’t know what to tell you,” said Mayor Craig.

In a statement, Steph Hannon, Google’s senior director of product management for exposure notifications, said there are “known challenges in using Bluetooth technology to approximate the exact distance between devices” and that the company is continually working to improve accuracy.

Company policies have also influenced usage trends. For example, in certain US states, iPhone users can turn on exposure notifications with one click by simply enabling a feature in their settings. However, Android users need to download a separate app. As a result, by May 10, about 9.6 million iPhone users in California had the notifications turned on, far exceeding the 900,000 app downloads on Android phones.

Google has set up its system in such a way that states work on a wide variety of devices and can be made available as quickly as possible.

Some public health experts admitted that the exposure warning system was an experiment where they and the tech giants learned and built improvements over time.

One problem they discovered early on: To prevent false positives, states review positive test results before a person can send exposure notifications. However, it can sometimes take days for local laboratories to send test results to health officials, limiting the ability of app users to quickly notify others.

In Alabama, for example, the government’s GuideSafe virus alert app has been downloaded around 250,000 times, according to Sensor Tower. However, state health authorities said they could confirm the positive test results from only 1,300 app users. That’s a much lower number than health officials expected, as more than 10 percent of Alabamians tested positive for the coronavirus.

“The app would be much more efficient if these processes were less manual and automated,” said Dr. Scott Harris, who oversees the Alabama Department of Health.

Colorado, which automatically issues verification codes to people who test positive, has reported higher usage rates. In California, UC San Diego Health has set up a dedicated hotline that app users can call if they haven’t received their verification codes.

Dr. Longhurst, the medical center’s chief information officer, said the California app proved useful as part of a larger statewide public health push that included wearing masks and virus testing.

“It’s not a panacea,” he said. But “it can be an effective part of a pandemic response.”

Categories
Health

Africa wants at the very least 20 million doses within the subsequent six weeks, WHO says

A medical worker injects a dose of the COVID-19 vaccine into a man at a hospital in Accra, capital of Ghana, on May 19, 2021.

Seth | Xinhua News Agency | Getty Images

Africa will need at least 20 million doses of AstraZeneca’s Covid-19 vaccine within the next six weeks to allow people who have already received the first round of shooting, the World Health Organization said on Thursday.

The data shows that one dose of the AstraZeneca vaccine is 70% effective for at least 12 weeks, but the second dose offers 81% protection against Covid over a longer period, according to the WHO. Antibodies have been seen in the body for up to six months after a dose.

In order for the continent to be able to vaccinate at least 10% of its population by September, another 200 million doses of an approved Covid-19 vaccine are urgently needed, according to the WHO.

As of Thursday, 28 million doses of Covid-19 had been administered in Africa by various drug manufacturers that have nearly 1.4 billion people, which is less than two doses for every 100 people on the continent. For comparison, more than 165 million people in the United States have received at least one dose of vaccine, according to the Centers for Disease Control and Prevention, almost half the country’s population.

“Africa needs vaccines now. Any break in our vaccination campaigns will result in deaths and a loss of hope,” said Dr. Matshidiso Moeti, WHO Regional Director for Africa. “We urge countries that have vaccinated their high-risk groups to speed up dose distribution to fully protect the most vulnerable.”

France has pledged to share half a million cans with six African countries over the next few weeks and has already sent 31,000 cans to Mauritania. Another 74,400 doses are to be delivered soon, the WHO announced.

The European Union has announced that it will send 100 million doses to low-income countries by the end of 2021, and the United States has pledged 80 million doses. Other countries around the world have also expressed an interest in sharing the doses. Countries in Africa that don’t use all of their cans are also sharing them with other countries on the continent, according to the WHO.

Redistributing vaccine doses is helpful, but expensive. WHO says Africa needs to increase its vaccine production capacity.

“Giving up intellectual property is a critical first step, but it needs to go hand in hand with sharing expertise and critical technologies,” the WHO wrote in a press release.

In Africa, 54 countries are involved in WHO efforts in more than 100 countries to submit a draft resolution to the World Health Assembly. The resolution aims to “strengthen local production, promote technology transfer and innovation and examine the agreement on trade-related aspects of intellectual property rights and intellectual property rights from the point of view of increasing local production,” according to the WHO.

Around 40 African countries have also followed WHO training on building production capacities. The WHO claims to be working with the African Union on a plan to support feasibility studies and technology transfers upon request.

“It’s too early to say if Africa is on the verge of a third wave. We do know, however, that cases are rising and the clock is ticking,” said Moeti.

Categories
Health

You Can Bid on NFTs Tied to Nobel Prize-Profitable Discoveries

How much will someone be willing to pay for a few pages of quarter-century-old bureaucratic university paperwork that have been turned into a blockchain-encoded piece of digital art?

The University of California, Berkeley, hopes quite a bit, and it is about to find out.

Berkeley announced on Thursday that it will auction the first of two digital art pieces known as nonfungible tokens, or NFTs, next week. The object being offered is based on a document called an invention and technology disclosure. That’s the form that researchers at Berkeley fill out to alert the university about discoveries that have potential to be turned into lucrative patents.

The title of the invention, from 1996, is “Blockade of T-Lymphocyte Down-Regulation Associated with CTLA-4 Signalling.”

The university hopes that potential bidders will be attracted to an early description of a revolutionary approach to treating cancer developed by James P. Allison, then a professor at Berkeley. He found a way to turn off the immune system’s aversion to attacking tumors and he showed that it worked in mice.

That advance eventually led to the creation of Yervoy, a drug for the treatment of metastatic melanoma, and Dr. Allison, who is now at the MD Anderson Cancer Center at the University of Texas, shared the Nobel Prize in Medicine in 2018.

Thus, the Berkeley disclosure form could be thought of as the scientific equivalent of Mickey Mantle’s rookie baseball card — a memento of the beginnings of greatness.

“I think of it almost as a history of science artifact,” said Richard K. Lyons, the chief innovation and entrepreneurship officer at Berkeley. “Imagine somebody saying, ‘I want to own the NFTs for the 10 most important scientific discoveries of my lifetime.’”

A 24-hour auction of the NFT of Dr. Allison’s invention disclosure will take place as early as June 2 using Foundation, an NFT auction marketplace that uses Ethereum, the cryptocurrency network of choice for NFT collectors.

Eighty-five percent of the proceeds will go to Berkeley to finance research, the remainder to Foundation. If the piece is later resold, Berkeley will receive 10 percent of the sale and Foundation 5 percent.

Because the making of an NFT requires a lot of computing power, part of the money the university earns from the NFT sale will be used for carbon offsets to compensate for the energy consumed, Berkeley officials said.

The second NFT that Berkeley plans to auction in the coming weeks will be the disclosure form describing the CRISPR-Cas9 gene editing invention by Jennifer A. Doudna, a professor of molecular and cell biology at Berkeley. She shared the 2020 Nobel Prize in Chemistry with Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens for their work on the technique.

NFTs have become trendy collectibles in recent months. A unique code embedded in a digital image or video serves as a record of its authenticity and is stored on a blockchain, the same technology that underlies digital currencies like Bitcoin. NFTs can then be bought and sold, just like baseball cards, and the blockchain ensures they cannot be deleted or counterfeited.

A dizzying array of documents, far beyond traditional works of art, have been sold as NFTs. Jack Dorsey, the founder of Twitter, sold an NFT of his first tweet for $2.9 million. Kevin Roose, a New York Times columnist, sold an NFT of his article about NFTs for more than half a million dollars. (The money went to The Times’s Neediest Cases Fund.)

The pages of Dr. Allison’s disclosure form, drawn from the Berkeley archives, make for mostly dry reading. There is a July 11, 1995, letter from Carol Mimura, a licensing associate at Berkeley, thanking Dr. Allison for contacting the university’s office of technology licensing and asking him to fill out some forms. Another page includes Berkeley’s patent policy.

The documents reflect quaintly archaic technologies used in the mid-1990s — typewriters, fax machines and handwritten notes. “I am scrambling to protect patentable matter before late July,” reads a memo from Dr. Mimura, now the assistant vice chancellor for intellectual property and industry research alliances.

A fax from Dr. Allison to Dr. Mimura includes a simple chart with three lines and 21 data points. “Carol — This is the data that has got us excited,” Dr. Allison has scribbled.

His research group was experimenting with colon cancer in mice, and blocking CTLA-4 — a protein receptor that acts as an on-off switch for the immune system — “led to the rejection of the tumor in 5/5 mice,” Dr. Allison wrote.

Until now, these forms, filed away, unseen, have had no value, Dr. Allison concedes.

“That very first exposure to the world is sort of like, ‘This is the invention disclosure,’” he said. “But once they’ve served that purpose, historically, they get no attention.”

The NFT idea was the brainchild of Michael Alvarez Cohen, director of innovation ecosystem development in Berkeley’s intellectual property office. He said part of the idea came after the publication of “The Code Breaker” by Walter Isaacson, a biography of Dr. Doudna. His friends and relatives told him that they had not known that much of the gene editing technology had originated at Berkeley.

“So I was kind of like, ‘Maybe we should post excerpts from the invention disclosure to help promote this,’” he said.

At the same time, he was following news about blockchain and NFTs.

“Then about a month ago, I put the two together,” Mr. Cohen said. Take the invention disclosures about Nobel-winning research like CRISPR, turn them into NFTs, “and drive awareness and also fund research by auctioning the NFTs.”

He sat on the idea for a while.

“I come up with a lot of ideas,” Mr. Cohen said. “Some of them are bone-headed and everything.”

Just over two weeks ago, he started discussing it with his colleagues, and quickly a plan fell into place. In addition to CRISPR, they decided to highlight Dr. Allison’s work.

The Allison NFT is more than a simple digital document. “It’s a combination of a lab notebook and digital art,” Mr. Cohen said. A single image includes 10 pages but one can zoom in and read the documents. “I really wanted to preserve the ability to read the history in addition to viewing the beauty of the image,” he said.

The designers of the NFT also included subtle nods to the initial resistance to Dr. Allison’s ideas. The pages are all slightly tilted, because “people looked at him askew,” Mr. Cohen said. “There’s a lot of little things like that in the art.”

Dr. Lyons was reluctant to predict how much the artwork would fetch at auction. “I’d be surprised if it went for less than $100,000,” he said. “It could go into seven figures. This is a new category, and it’s hard to price anything that is a new category.”

Categories
Health

FDA official says coronary heart challenge presumably linked to pictures is uncommon

A healthcare worker administers a dose of a Pfizer-BioNTech Covid-19 vaccine to a child at a pediatrician’s office in Bingham Farms, Michigan, U.S., on Wednesday, May 19, 2021.

Emily Elconin | Bloomberg | Getty Images

A heart inflammation condition in adolescents and young adults who received Covid-19 vaccines appears to be very rare and it remains unclear if the issue is actually related to the shots, the Food and Drug Administration’s top vaccine regulator, Dr. Peter Marks, said Thursday.

The Centers for Disease Control and Prevention’s vaccine safety group said last week it was looking into a condition called myocarditis, which is an inflammation of the heart muscle, in a “relatively few” people who received Covid vaccinations.

Myocarditis can affect one’s heart muscle and heart electrical system, “reducing its ability to pump and causing rapid or abnormal heart rhythms,” according to the Mayo Clinic.

The cases were predominantly in adolescents and young adults and usually occurred within four days after getting the shot, according to the CDC. The condition was seen more often in men and most cases appear to be mild, the agency said, though officials are following up with the patients.

“We still don’t know whether this is truly related to the vaccine,” Marks, director of the FDA’s Center for Biologics Evaluation and Research, said during a virtual Q&A event with the COVID-19 Vaccine Education and Equity Project.

The CDC is coordinating its investigation with the FDA, which recently authorized the Pfizer-BioNTech vaccine for adolescents ages 12 to 15. The vaccine has been available for Americans 16 and up since December. Vaccines from Moderna and Johnson & Johnson are available to those 18 and older.

Health experts say finding rare side effects once a vaccine or drug is administered to the general population is common and if myocarditis turns out to be related to the Covid vaccine, the risk is negligible when compared with the risks of being infected with Covid-19.

Marks, who has been at the FDA for nearly a decade, added Thursday that the “handful” of cases reported have been “very mild, lasting a day or two” and usually happened after a second dose.

“My kids are a little older, but I wouldn’t hesitate to vaccinate my children, just because this is a pretty rare finding and we really don’t know yet if it’s truly related” to the vaccines, he said.